FDA Committee Holds Full Day Meeting on Safety and Effectiveness of Covid-19 Booster Dose
I spent much of Friday (9/17/2021) listening to live submissions from an array of witnesses on whether the FDA should give approval to Pfizer vaccine booster doses at this time. The session was educational in many ways, including the range of considerations that the FDA considers when making such decisions. The Committee was asked, towards the end of the afternoon, to vote on the following question: